Smith & Wesson Brands에 대한 매도 수량은 투자자에게 Smith & Wesson Brands의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Smith & Wesson Brands (NASDAQ:SWBI) 주식, 공매도 수량 보고

Smith & Wesson Brands

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVGO

SWBI

금요일 아침 (현지 시간 기준) 미국 주식 선물이 혼조세를 보이는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같다: 1. 월스트리트는 ABM 인더스트리즈(NYSE:ABM)가 개장 전 매출 20억 4천만 달러에 주당 86센트의 분기 이익을 보고할 것으로 예상하고 있다. ABM의 주식은 시간 외 거래에서 3.4% 상승한 $58.00를 기록했다.

금요일 주목해야 할 주식: 브로드컴, ABM 인더스트리즈 그리고 3종목

After-Hours Center

Movers

스미스 앤드 웨슨 브랜드(NASDAQ:SWBI)의 주가는 회사가 목요일 4분기 재무 실적을 발표로 급등했으나 이후 하락했다. 보고서의 주요 수치는 다음과 같다. 주요 내용 (The Details): 스미스 앤드 웨슨은 분기별 주당 순이익을 45센트로 보고했는데, 이는 분석가들의 합의 추정치인 34센트를 32.35%나 앞선 것이다.

스미스 앤드 웨슨: 예상보다 좋은 4분기 실적 발표 후 주가는 초반 상승을 반납하고 하락

Smith & Wesson Brands, Inc. - Common Stock

Smith & Wesson Brands Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

BJDX

SMST

LIFW

SMCX

LIFWW

Numinus Wellness Inc. (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTCQX">NUMIF</a>), a leader in <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">psychedelic-assisted mental health care</a>, has <a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Announces-Sale-of-Clinics-and-Unique-Data-Partnership-to-Increase-Access-to-Mental-Health-Care/default.aspx">announced</a> a definitive agreement with Stella, an interventional psychiatry practice, to sell its five wellness clinics in Utah for a total of $3.53 million. The transaction, expected to close by November 30, marks a strategic shift for Numinus, as it pivots towards <a href="https://www.benzinga.com/markets/cannabis/24/09/40845569/mdma-therapy-for-ptsd-faces-fda-delay-are-there-other-ways-forward">developing technology-driven solutions</a> aimed at enhancing the efficiency of mental health care providers.
<h3 class="wp-block-heading">Tech Partnership To Redefine Mental Health Clinics</h3>
In addition to the sale, Numinus and Stella will collaborate on a data-sharing initiative to launch an innovative clinic management platform. By leveraging operational insights from Stella's 12 clinics, Numinus plans to develop a software solution designed to streamline clinic operations, enhance patient outcomes and support insurance reimbursement processes.
"This transaction marks an exciting new chapter in Numinus' strategy to reshape behavioral health care," said Payton Nyquvest, founder and CEO of Numinus. "Leveraging our expertise in patient care, we're now accelerating our mission by focusing on cutting-edge technology solutions. Through our partnership with Stella, we gain unprecedented access to operational data that will enable us to develop a SaaS (software as a service) solution to redefine how clinics operate."
<h3 class="wp-block-heading">Stella Takes Over Utah Operations</h3>
Stella, known for its focus on treating PTSD, anxiety and depression through biological modalities, will assume control of Numinus' Utah clinics. The acquisition includes an upfront payment of $2.08 million, followed by $750,000 in installments throughout 2025, and up to $700,000 in deferred compensation.
"Stella's expansion into Utah brings additional life-changing treatments to the community while supporting Numinus' broader tech initiatives," stated Michael Gershenzon, co-founder and CEO of Stella. "This partnership reflects our commitment to improving behavioral health systems and processes, ultimately enhancing patient care."
<h3 class="wp-block-heading">An Asset-Light Business Model With Enhanced Focus</h3>
With the sale of its clinics, Numinus will shift towards an asset-light model, focusing on its business units like Cedar Clinical Research and the Numinus Network. The strategy aims to integrate clinical research, practitioner training and technology solutions, supporting mental health providers worldwide. The move is part of a broader effort to ease the operational burdens faced by healthcare professionals, particularly as demand for treatments like <a href="https://www.benzinga.com/topic/ketamine-therapy">ketamine</a> and Spravato continues to rise.
"Stella will bolster our clinical solutions offering, leveraging their deep expertise in patient care," Nyquvest added. "We expect strong demand for our Numinus Network Solutions as mental health practitioners navigate growing requests for care."
Cover image made with AI

Cannabis

Psychedelics

NUMIF

Numinus Wellness Sells US Clinics, Partners With Stella For Tech-Driven Mental Health Solutions

President-elect Donald Trump has chosen former Representative Doug Collins (R-GA) to lead the <a href="https://www.benzinga.com/cannabis">U.S. Department of Veterans Affairs (VA). </a>
The decision has sparked discussions about how the agency might handle medical cannabis issues, given his inconsistent track record on the issue, as <a href="https://www.marijuanamoment.net/trumps-pick-to-lead-va-voted-against-letting-agency-doctors-recommend-medical-marijuana-to-veterans-before-he-adopted-a-pro-reform-position/">reported</a> Marijuana Moment.
<h3 class="wp-block-heading">Collins' Record On Cannabis</h3>
During his time in Congress, Collins opposed efforts to expand access to medical cannabis for veterans. Between 2014 and 2016, he voted against three proposals that would have allowed VA doctors to recommend cannabis to their patients.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/11/42018478/trumps-cabinet-choices-will-his-administration-support-or-restrict-cannabis">Trump&#8217;s Cabinet Choices: Will His Administration Support Or Restrict Cannabis?</a>
Collins' views began to shift in 2019. He supported the STATES Act, which would protect state marijuana programs from federal interference, and co-signed a letter with Rep. Matt Gaetz (R-FL), urging Congress to take action on cannabis policy. 
"We believe this Committee and this Congress must act to clarify the rights and responsibilities, relative to cannabis, of individuals, physicians, businesses, medical patients, and law enforcement officials," they wrote.
Later that year, Collins backed a bipartisan bill to protect banks that serve marijuana businesses in states where it is legal. However, he did not take part in a 2020 vote on federal cannabis legalization.
<h3 class="wp-block-heading">Collins' Stance On Psychedelics</h3>
When it comes to psychedelics, there isn't much known about Collins's stance. However, his shifting views on cannabis policy hint that he could be open to exploring different approaches.
<h3 class="wp-block-heading">Cannabis At The VA</h3>
VA policy has long prohibited its doctors from recommending cannabis, citing marijuana's classification as a Schedule I controlled substance under federal law. This stance has remained consistent across both Republican and Democratic administrations, despite growing support for change in Congress.
Recent efforts to address this issue include a Senate Appropriations Committee request for the VA to explore cannabis as an alternative to opioids. Lawmakers have also introduced measures that would allow VA doctors to recommend cannabis in states where it is legal. These efforts have gained bipartisan support, but none have yet become law.
Veterans service organizations have pushed for further reforms, including expanded research into the potential benefits of cannabis. Last year, a Senate committee approved a bill to study cannabis for veterans with certain medical conditions, but it failed to advance to a floor vote.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42017583/trumps-go-wild-on-health-plan-puts-rfk-jr-in-charge-what-it-means-for-cannabis-and-psychedelics-reform">Trump&#8217;s &#8216;Go Wild On Health&#8217; Plan Puts RFK Jr. In Charge: What It Means For Cannabis And Psychedelics Reform</a></li>
</ul>
Cover image made with AI.

Government

Politics

Trump-Appointed Doug Collins To Lead VA: What's Next For Cannabis and Psychedelics In Veterans' Healthcare?

Chardan Capital analyst Daniil Gataulin maintains Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) with a Buy and maintains $6 price target.

Price Target

Analyst Ratings

CLSD

Chardan Capital Maintains Buy on Clearside Biomedical, Maintains $6 Price Target

Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) with a Buy and maintains $11 price target.

CGTX

Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $11 Price Target

Telsey Advisory Group analyst Cristina Fernandez maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Outperform and maintains $165 price target.

Telsey Advisory Group Maintains Outperform on Williams-Sonoma, Maintains $165 Price Target

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation –
– Syndax to host conference call today at 6:00 p.m. ET –
WALTHAM, Mass., Nov. 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj&#xAE; (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older. The FDA previously granted Breakthrough Therapy and Fast Track designations as well as Priority Review for Revuforj. The New Drug Application (NDA) received approval through the FDA's Real Time Oncology Review (RTOR) program.

Biotech

General

SNDX

Syndax Announces FDA Approval Of Revuforj, The First And Only Menin Inhibitor To Treat Adult And Pediatric Patients With Relapsed Or Refractory Acute Leukemia With A KMT2A Translocation

IT Tech Packaging (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITP#AMEX">ITP</a>) reported quarterly losses of $(0.20) per share. This is unchanged from the same period last year. The company reported $25.08 million in sales this quarter. This is a 59.03 percent increase over sales of $15.77 million the same period last year.

IT Tech Packaging Q3 EPS $(0.20), Same YoY, Sales $25.08M Up From $15.77M YoY

RumbleOn, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) (the "Company" or "RumbleOn") announced today that the close of business (4:00 p.m. Central Time) on November 25, 2024 has been fixed as the record date (the "Record Date") for its previously announced proposed $10.0 million registered equity rights offering (the "Rights Offering"), which was announced in a Form 8-K filed with the U.S. Securities and Exchange Commission ("SEC") on November 12, 2024.

Offerings

RMBL

RumbleOn Announces That The Close Of Business On November 25, 2024 Has Been Fixed As The Record Date For Its Previously Announced Proposed $10M Registered Equity Rights Offering

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Outperform and maintains $8 price target.

EWCZ

Telsey Advisory Group Maintains Outperform on European Wax Center, Maintains $8 Price Target

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20241115-1475367/1475367_4rcm.pdf</a>

FOUR

Shift4 Payments Will Replace R1 RCM In The S&P Midcap 400 Effective Prior To The Opening Of Trading On Wednesday, November 20

China Green Agriculture, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CGA#NYSE">CGA</a>) has changed its name to Enlightify Inc., effective November 25, 2024. Its ticker symbol will change to ENFY effective November 25, 2024, and it is expected to begin trading under that symbol on November 26, 2024. The Company mainly produces and distributes humic acid-based compound fertilizers, other varieties of compound fertilizers and agricultural products through its subsidiaries in China.

China Green Agriculture Changes Name to Enlightify Inc.; Its Ticker Symbol Will Change To 'ENFY' Effective November 25, 2024, And It Is Expected To Begin Trading Under That Symbol On November 26, 2024

Alpha Cognition (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOG#NASDAQ">ACOG</a>) reported quarterly losses of $(0.31) per share. This is a 63.1 percent increase over losses of $(0.84) per share from the same period last year.

ACOG

Alpha Cognition Q2 EPS $(0.31) Up From $(0.84) YoY

D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRXP#NASDAQ">NRXP</a>) with a Buy and maintains $31 price target.

NRXP

D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $31 Price Target

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Here's the major earnings after the close today

Smith & Wesson Brands, Inc. (SWBI) Q1 2025 Earnings Call Transcript

Smith & Wesson Brands declares $0.13 dividend

In a report released today, Mark Smith from Lake Street maintained a Buy rating on Smith & Wesson Brands (SWBI – Research Report), with a price tar...

Lake Street Remains a Buy on Smith & Wesson Brands (SWBI)

Dividend Champion, Contender, And Challenger Highlights: Week Of September 15

Dividend Champion, Contender, And Challenger Highlights: Week Of September 29

Small-cap stocks offer strong growth potential as they are often in the early stages of expansion. Also, these stocks tend to be undervalued, providing opportunities for investors to find hidden gems. Thus, quality small-cap value stocks Caleres (CAL), Smith & Wesson Brands (SWBI), and Ribbon Communications (RBBN) could be ideal candidates to buy now. Read more... Qualities like high growth prospects, impressive yield possibilities, and long-term growth potential make small-cap stocks worth considering. Also, with the swiftly recovering U.S. economy, the opportunities for this segment of stocks are expanding rapidly.
Considering the bright outlook, it could be wise to invest in current Wall Street favorite small-cap value stocks Caleres, Inc. (<a href="https://stocknews.com/stock/CAL/">CAL</a>), Smith &amp; Wesson Brands, Inc. (<a href="https://stocknews.com/stock/SWBI/">SWBI</a>), and Ribbon Communications Inc. (<a href="https://stocknews.com/stock/RBBN/">RBBN</a>) for potential returns.
As the U.S. economy continues to grow at a steady pace, it presents an appealing opportunity for investors to invest in small-cap stocks. In 2024, the performance of the U.S. economy has improved with each quarter. The <a href="https://tradingeconomics.com/united-states/gdp-growth">US economy grew</a> 1.6% in the first quarter of 2024 and jumped to an annualized rate of 3% in the second quarter of 2024.
Federal government spending, rising business investments, and growing consumer spending fueled the growth. Also, for the third quarter, GDP is expected to continue expanding at a similar pace throughout the remainder of this year.
With this economic trajectory, adding small-cap stocks to the portfolio could be ideal. <a href="https://www.investopedia.com/terms/s/small-cap.asp">Small-cap stock</a> is a company that has a market capitalization below $2 billion. Owing to their small capitalization, they offer more growth opportunities compared to large-cap entities. In the last year, the <a href="https://www.cnbc.com/quotes/.RUT">Russell 2000 Index</a> returned 22.98%, and <a href="https://www.spglobal.com/spdji/en/indices/equity/sp-global-smallcap/#overview">S&amp;P Global SmallCap</a> gained 20.75%.
Also, historically, small-cap stocks have outperformed large-cap stocks with their potential, and they offer the possibility of significant returns as they expand and capture higher market share. Further, continuous innovations and investment in technology have created new opportunities for the companies.
Considering the economy's bright prospects, investors could consider adding fundamentally sound small-cap value stocks CAL, SWBI, and RBBN to their portfolios.
Let's discuss the fundamentals of these stocks in detail:
Caleres, Inc. (<a href="https://stocknews.com/stock/CAL/">CAL</a>)
CAL engages in the retail and wholesale of footwear business internationally. The company operates through Famous Footwear and Brand Portfolio segments. The company provides licensed, branded, and private-label athletic, casual, and dress footwear products.
In terms of forward <a href="https://www.investopedia.com/terms/p/price-to-salesratio.asp">Price/Sales</a>, CAL is trading at 0.42x, 55.2% lower than the industry average of 0.94x. Likewise, the stock's forward Price/Book multiple of 1.60 is 38.9% lower than the industry average of 2.63. Also, its forward EV/EBITDA of 7.36x is 27.7% lower than the industry average of 10.18x.
On August 29, CAL's Board of Directors declared a regular quarterly cash dividend of $0.07 per share paid on September 27, 2024, to shareholders of record as of September 13, 2024. The company has paid a consecutive quarterly dividend for more than 100 years.
CAL pays an annual dividend of $0.28, which translates to a yield of 0.85% at the current share price. Its four-year average dividend yield is 1.20%.
On August 22, CAL's lead brand, Allen Edmonds, launched The Reserve Collection. The exclusive capsule is the pinnacle expression of the art of American shoemaking and reflects Allen Edmond's commitment to quality and craftsmanship for over a century.
During the second quarter that ended August 3, 2024, CAL reported net sales of $683.32 million, and its gross profit was $310.88 million. Adjusted net earnings attributable to CAL came in at $29.96 million and $0.85 per share for the quarter, respectively.
As of August 3, 2024, the company's total assets stood at $2.02 billion, compared to $1.90 billion as of July 29, 2023.
Street expects CAL's revenue and EPS for the fiscal year (ending January 2026) to increase 3.3% and 12% year-over-year to $2.85 billion and $4.53, respectively. Furthermore, the company has topped the consensus EPS estimates in three of the four trailing quarters.
Over the past year, CAL's stock has surged 15.7% to close the last trading session at $32.89.
CAL's <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a> reflect its robust outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.
CAL has a B grade for Value and Quality. It is ranked #19 out of 59 stocks in the A-rated <a href="https://stocknews.com/category/fashion-luxury/">Fashion &amp; Luxury</a> industry.
In addition to the POWR Ratings we've stated above, we also have CAL's ratings for Growth, Momentum, Sentiment, and Stability. Get all CAL ratings <a href="https://stocknews.com/stock/CAL/">here</a>.
Smith &amp; Wesson Brands, Inc. (<a href="https://stocknews.com/stock/SWBI/">SWBI</a>)
SWBI designs manufactures and sells firearms globally. The company provides handguns, long guns, handcuffs, suppressors, and other firearm-related products under the Smith &amp; Wesson, M&amp;P, and Gemtech brands.
SWBI's forward non-GAAP P/E is trading at 12.33x, 28.2% lower than the industry average of 17.17x. Also, the stock's forward EV/Sales multiple of 1.16 is 10.9% lower than the 1.30 industry average. Similarly, its forward EV/EBITDA of 6.19x is 39.3% lower than the industry average of 10.18x.
For the first quarter that ended July 31, 2024, SWBI's net sales amounted to $88.33 million. The company's non-GAAP gross profit was $25.37 million. Also, its Non-GAAP Adjusted EBITDAS came in at $9.90 million for the quarter.
In addition, as of July 31, 2024, the company's cash and cash equivalents and total assets were $35.51 million and $571.27 million, respectively.
Analysts expect SWBI's revenue and EPS for the second quarter (ending October 2024) to grow 6.9% and 17.9% year-over-year to $133.52 million and $0.17, respectively. Further, the company topped the consensus revenue estimates in three of the trailing four quarters.
Shares of SWBI have plunged 2% over the past year to close the last trading session at $12.88.
SWBI's sound fundamentals are reflected in its POWR Ratings. The stock has a B grade for Value and Momentum. Within the <a href="https://stocknews.com/category/athletics-recreation/">Athletics &amp; Recreation</a> industry, SWBI is ranked #6 of 34 stocks.
<a href="https://stocknews.com/stock/SWBI/">Click here</a> to access additional ratings of SWBI for Growth, Quality, Sentiment, and Stability.
Ribbon Communications Inc. (<a href="https://stocknews.com/stock/RBBN/">RBBN</a>)
RBBN provides communications technology internationally. It operates in two segments, Cloud and Edge; and IP Optical Networks. The company offers software and hardware products, solutions, and services for voice-over internet protocol communications, voice-over long-term evolution, voice-over 5G communications, and unified communications and collaboration.
In terms of forward EV/EBIT, RBBN is trading at 9.12x, 54.2% lower than the industry average of 19.90x. Further, the stock's forward Price/Sales multiple of 0.65 is 77.4% lower than the industry average of 2.85. Also, its forward non-GAAP P/E of 12.96x is 45.6% lower than the industry average of 23.81x.
On July 22, RBBN and Leading fiber broadband and technology provider Converge ICT Solutions Inc. (CNVRG) collaborated to pioneer in the Philippines with a leading-edge Apollo optical networking system, which will optimize data transmission across the internet provider's backbone network.
RBBN reported revenue of $192.62 million during the second quarter, which ended June 30, 2024, and its gross profit grew 6.4% from the year-ago value to $97.87 million. The company's non-GAAP adjusted EBITDA stood at $22 million.
In addition, the company's non-GAAP net income and non-GAAP EPS amounted to $8.52 million and $0.05, up 10% and 25% from the prior year's quarter, respectively.
Street expects RBBN's revenue for the third quarter (ended September 2024) to increase 4.4% year-over-year to $212.14 million, while its EPS for the same quarter is expected to grow 16% year-over-year to $0.06. Also, for the fiscal year 2024, the company's revenue and EPS are expected to grow 1.7% and 14.3% year-over-year to $840.72 million and $0.24.
Shares of RBBN have soared 21% over the past year to close the last trading session at $3.11.
RBBN's POWR Ratings reflect its bright prospects. The stock has an overall rating of B, which equates to a Buy in our proprietary rating system.
The stock has a B grade for Value and Growth. RBBN is ranked #6 of 45 stocks in the <a href="https://stocknews.com/category/technology-communication-networking/">Technology – Communication/Networking</a> industry.
<a href="https://stocknews.com/stock/RBBN/">Click here</a> to access additional ratings of RBBN for Momentum, Quality, Sentiment, and Stability.
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
CAL shares were trading at $32.60 per share on Wednesday afternoon, down $0.29 (-0.88%). Year-to-date, CAL has gained 6.74%, versus a 20.81% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Rjkumari Saxena</h2> <img src='https:/wp-content/uploads/2024/04/Rajkumari-Saxena_Image-1.jpeg' style="float:left; padding:5px;width:125px;">Rajkumari started her career as a writer but gradually shifted her focus to financial journalism, leveraging her educational background in Commerce. Fascinated by the interplay of business and economic shifts in equities, she aspires to evolve as an analyst. With a knack for simplifying complex financial concepts, her mission is to empower investors with insights that lead to profitable decisions.<a href="https://stocknews.com/authors/?author=rajkumari-saxena">More...</a>The post <a href=https://stocknews.com/news/cal-swbi-rbbn-3-small-cap-value-stocks-wall-street-loves-right-now/>3 Small-Cap Value Stocks Wall Street Loves Right Now</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Small-Cap Value Stocks Wall Street Loves Right Now

Smith & Wesson Brands: The Upcoming Election Is The Ultimate Catalyst

SA Asks: Which consumer stocks could rise or fall on a Harris win?

FBI firearm background checks track higher ahead of the U.S. election

ALLE

AMSF

AOUT

APLO

BPOP

CADE

CBSH

CCBG

CFFI

CHCO

CHRW

CINF

CMCSA

CSCO

CTBI

CTVA

CUBE

DOCU

EQIX

ERIE

EVRG

EXPO

FFIN

FISI

FITB

FMAO

FRME

FULT

FUNC

GAIN

GOLF

GWRE

HBNC

HLNE

HWBK

INDB

INGR

JJSF

LAND

LOGI

LRCX

LTRX

LULU

MBIN

MBWM

MDLZ

MOFG

MORN

ODFL

OTEX

PATH

POWW

PRGO

RBBN

RBCAA

RGLD

SAMG

SBAC

SCVL

SFBS

SFNC

SLGN

SMAR

SPTN

SPWH

SSTI

SYBT

TCBK

THFF

UBSI

UMBF

UNTY

UTMD

VICI

VSTO

WASH

WSBC

ZUMZ

Press Releases

Newman Ferrara with Congregations of Catholic Sisters File Suit Related to Smith & Wesson's Marketing and Sale of AR-15 Assault Rifles (NASDAQ: SWBI)

Comments

Smith & Wesson Brands

매도 수량

Smith & Wesson Brands (NASDAQ:SWBI) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌